Peer Review

Clancy joins the new team at Alexion, investment banker joins Flagship, Deeg quickly rises through ranks at Regulus

→  CFO Paul Clancy left Biogen after 16 years to join Alexion. Under new CEO Ludwig Hantson, Alexion has been undergoing major staffing changes and there is talk of big pipeline changes to come. Biogen is on the hunt for a replacement. But in the meantime Biogen chief accounting officer Greg Covino will fill in for Clancy.

→  Top JPMorgan investment banker Stephen Berenson left the banking world behind to join the startup crew at Flagship in hopes of doing something “completely new and completely transformative.”

Along with its $27 million round, Checkmate CEO Art Krieg also announced that he had hired Forum veteran Karen Brennan as the new chief operating officer. Brennan had earlier worked at Millennium/Takeda.

→  Mark Deeg was promoted to chief medical officer at Regulus. He joined the company in April as vice president of translational medicine.

→  Barbara Duncan was appointed chairperson of the audit committee on the board of directors at Ovid. She previously served as CFO and treasurer at Intercept.

→  Tony Tramontin joined Axcella as chief scientific officer and senior vice president of research & development. He was previously a partner in McKinsey & Company’s Global Healthcare Practice.

→  SetPoint appointed translational medicine consultant, David Chernoff as chief medical officer.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,100+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Director Process Development
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->